{"id":"NCT00631319","sponsor":"Mallinckrodt","briefTitle":"A Double-blind Study of Controlled Release OROS Hydromorphone Compared to Placebo in Patients With Chronic Osteoarthritis (OA) Pain","officialTitle":"A Phase III, Flexible Dose Titration Followed by a Randomized Double-Blind Study of Controlled Release OROS Hydromorphone HCL Compared to Placebo in Patients With OA Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-02","primaryCompletion":"2009-04","completion":"2009-06","firstPosted":"2008-03-07","resultsPosted":"2020-08-26","lastUpdate":"2020-09-16"},"enrollment":343,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Pain"],"interventions":[{"type":"DRUG","name":"OROS hydromorphone","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"OROS Hydromorphone","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate the efficacy of OROS Hydromorphone in reducing moderate to severe chronic pain in patients with Osteoarthritis (OA) Pain","primaryOutcome":{"measure":"Patient Diary-derived Numeric Rating Scale (NRS) Pain Intensity Change From Baseline to Week 12 or Final Visit of the Double-blind Phase","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"OROS Hydromorphone","deltaMin":0.6,"sd":2.02},{"arm":"Placebo","deltaMin":0.6,"sd":1.87}],"pValues":[]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":338},"commonTop":["Constipation","Nausea","Headache","Vomiting","Somnolence"]}}